Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

New Drug Class Shows Activity in Refractory Multiple Myeloma

December 10th 2013

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Dr. Laubach on the Efficacy of Daratumumab in Myeloma

December 10th 2013

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma

December 9th 2013

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Treating Precursor Disease May Stall Multiple Myeloma Progression

December 8th 2013

Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.

Longer Bortezomib Duration Linked to Improved Survival in Multiple Myeloma

December 8th 2013

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

New Approaches Explored in Relapsed/Refractory Multiple Myeloma

October 31st 2013

Several protocols of novel immune and targeted agents show promise alone and in combination, including monoclonal antibodies, immune therapies, and newer proteasome inhibitors.

Novel Proteasome Inhibitors for Multiple Myeloma

October 17th 2013

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

No Age Limit for Bone Marrow Transplantation

October 10th 2013

Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.

Doxil Availability Once Again in Question

October 9th 2013

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Studies Highlight Newly Approved and Novel Multiple Myeloma Treatments

July 26th 2013

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide, as well as research involving the novel agents daratumumab and elotuzumab.

Project Aims to "Bridge the Gap" From Remission to Cure in Multiple Myeloma

June 21st 2013

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.

Elotuzumab Combination Therapy Shows Promise in Previously Treated Multiple Myeloma

June 20th 2013

Patients with previously treated multiple myeloma responded well to therapy with the monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone, with a high objective response rate and longer progression-free survival.

Charting the Course in Myeloma: Durie Keeps Standards, New Goals in Sight

June 10th 2013

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.

Breakthrough Designation Granted to Daratumumab for Double Refractory Multiple Myeloma

May 1st 2013

An investigational monoclonal antibody called daratumumab has received breakthrough therapy designation from the FDA for the treatment of patients with double refractory multiple myeloma.

Dr. Landgren on the Standard of Care in Multiple Myeloma

April 29th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for patients with multiple myeloma.

Dr. Landgren on Carfilzomib and Pomalidomide

April 10th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.

Using the New Therapeutic Options in Multiple Myeloma

April 5th 2013

There have been waves of advancements in the treatment of multiple myeloma and further exploration of existing regimens and research into novel therapeutics hold the promise of advances.

Dr. Berenson Discusses New Potential Targets in Myeloma

April 4th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, comments on new potential targets in myeloma.

Dr. Landgren Discusses Risk and Treatment in Myeloma

March 28th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

Dr. Berenson on Carfilzomib in Refractory Multiple Myeloma

March 15th 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, Chief Executive Officer, Oncotherapeutics, discusses the a study of carfilzomib as a replacement for bortezomib for multiple myeloma patients refractory to a bortezomib-containing combination regimen.